INTRODUCTION
Ovarian cancer remains the most lethal gynecological malignancy in the United States and Canada (Seiden, 2015) . Among the different subtypes of the disease, high-grade serous ovarian cancer (HGSOC) is by far the most common, making up roughly two thirds of cases (Reid et al., 2017) . Currently, initial treatment consists of a cytoreductive surgery followed by six cycles of a platinum agent-and taxane-based chemotherapeutic regimen (Network, 2017) . Although primary response rates are high, frailty associated with multiple rounds of chemotherapy and eventual cancer cell drug resistance limit long-term five-year overall survival to around 40% (McGuire, 2009 ). Nevertheless, the high initial response rates suggest that a greater understanding of the molecular basis of the cellular responses involved could provide avenues to improve therapeutic approaches.
Cellular responses to stress like DNA damage induced by radio-or chemotherapy are termed cell fate decisions. These include repair or bypass of the damage, cell death (programmed or catastrophic), and cellular senescence (permanent growth arrest) . Senescent cells are characterized by several senescence-associated (SA) hallmarks that contribute to their biological functions. Among these, most prominent are the SA proliferation arrest (SAPA), SA apoptosis resistance (SAAR) and the micro-environmentally active SA secretory phenotype (SASP) (Coppe et al., 2008; Goldstein et al., 2005; Hayflick and Moorhead, 1961; Hernandez-Segura et al., 2018; Malaquin et al., 2016; . The SAPA functions as a direct tumor suppressive mechanism and is largely mediated by two key tumor suppressor pathways: p53/p21 WAF1 and p16INK4A/Rb (Beausejour et al., 2003; Campisi and d'Adda di Fagagna, 2007; Narita et al., 2003; Rodier et al., 2007) , although many other pathways contribute a large degree of redundancy in this program (Gonzalez et al., 2016; Hernandez-Segura et al., 2018; Munoz-Espin and Serrano, 2014) . It is thought that the stability of the SAPA is maintained to a great extent through SA chromatin remodeling, in particular through the formation of SA heterochromatin foci (SAHF) at the loci of proliferation-promoting genes Zhang et al., 2007) . Though SA chromatin remodeling remains incompletely understood, the downregulation of nuclear lamin B1 seems facilitate this process, and is also a senescence hallmark (Freund et al., 2012; Shah et al., 2013) . Alternatively, the growth factors, cytokines, chemokines, extracellular proteases, and extracellular matrix proteins that compose the SASP mediate senescent cells functions in tissue repair (Coppe et al., 2008; 4/36 Freund et al., 2010; Freund et al., 2011; Hoenicke and Zender, 2012; Krizhanovsky et al., 2008; Malaquin et al., 2016; Rodier et al., 2009 ). In the context of cancer, senescence is undoubtedly beneficial in its role as a barrier to malignant transformation in pre-neoplastic lesions (Campisi and d'Adda di Fagagna, 2007; Kuilman et al., 2010; Rodier et al., 2007) , and therapy-induced senescence (TIS) in damaged cancer cells may also be advantageous by preventing tumor cell growth (Chang et al., 1999; Collado and Serrano, 2010; Gonzalez et al., 2016) . However, alterations to tissue microenvironments caused by SASP must be evaluated contextually (Coppe et al., 2010) . For example, in a mouse model of liver cancer, the microenvironment created by the presence of senescent cells was shown to promote the immune clearance of damaged cancer cells, suggesting that senescence could enhance the therapeutic response (Xue et al., 2007) . In contrast, TIS was demonstrated to promote treatment resistance in a mouse lymphoma model by creating survival niches for residual cancer cells (Gilbert and Hemann, 2010; Rodier et al., 2009 ). Currently, whether TIS is an overall beneficial or detrimental process during human cancer treatment remains largely unknown.
A few studies have begun to shed light on the relevance of senescence in ovarian cancer. For example, evidence of a DNA-damage response (DDR) barrier, often associated with senescence, has been reported in hyperplastic fallopian tubes, suggesting that senescence acts as a tumor suppressive mechanism in this context to prevent the progression of pre-neoplastic lesions to HGSOC, perhaps applying a selective pressure responsible for the extremely high penetrance of p53 mutations in this disease (Jones and Drapkin, 2013) . Also, the induction of senescence via manipulation of a variety of exogenous or endogenous factors after malignant transformation has been shown in immortalized cell lines derived from various ovarian cancer subtypes, demonstrating that ovarian cancer cells can be forced into senescence via drug exposure (Chang et al., 1999) , growth factor overexpression (Bitler et al., 2011) , steroid exposure (Diep et al., 2013) , or select miRNA overexpression (Liu et al., 2014; Weiner-Gorzel et al., 2015) . However, recent studies suggest that immortalized ovarian cancer cell lines likely do not reflect the full spectrum of human disease due to clonal derivation and low spontaneous immortalization rates (Ince et al., 2015; Verschraegen et al., 2003) , highlighting the need for further research in this field.
Here, using human HGSOC primary cells, patient tissues, and their associated clinical data, we find that culture stress and chemotherapy-induced DNA damage trigger senescence in primary consistent with previous observations (Ince et al., 2015; Verschraegen et al., 2003) reinforcing the idea that spontaneous immortalization of HGSOC primary cells is a relatively rare event.
We further explored this apparent senescence response using Affymetrix gene expression analysis profiles from 42 independent HGSOC primary cultures at various passages within the culture lifespan (from early to late passages). Individual cultures were first assigned a proliferation status using unsupervised clustering for E2F-response gene activity (Fig. S1 ).
Proliferating early passage cells (≤50% lifespan completed) were then compared to slowproliferating late passage cells (≥75% lifespan completed), revealing significant gene set enrichment analysis (GSEA) to multiple senescence GSEA signatures (15/22 gene sets; Fig.   S1d ), including very significant enrichment for replicative senescence (Fig. 1c) .
To further confirm key senescence hallmarks directly, we serially passaged five HGSOC primary cultures (TOV959D, TOV3011D, TOV2356, TOV2267, TOV3207G). Just like normal ovarian surface epithelial cells (NOV1341G) and as expected during culture stress-induced senescence HGSOC primary cultures gradually ceased proliferation (Fig 1d) . When compared to early passage cells from their matched parental culture, late passage normal and cancer cells displayed increased senescence-associated beta-galactosidase activity (SA-β-Gal) and decreased DNA synthesis . Tumor suppressor genes driving senescence are often mutated Calvo et al. / 2018 7/36 in cancer (Gonzalez et al., 2016; Hanahan and Weinberg, 2011) . Indeed, the well-known tumor suppressor TP53, a master mediator of damage-induced senescence, is mutated in >95% cases of HGSOC (Ahmed et al., 2010; Cancer Genome Atlas Research, 2011; Jones and Drapkin, 2013) ( Fig. S2c) . However, a quick analysis of The Cancer Genome Atlas (TCGA) large ovarian cystadenocarcinoma cohorts (currently 617 combined cases) reveal that p16INK4A (gene CDKN2A), another important mediator of SAPA and a senescence biomarker , is mutated in less than 5 % of HGSOC cases (Fig. S2c) . We thus performed an immunostaining for p16INK4A concomitantly with a DNA synthesis assay on early and late passage HGSOC cells. Compared to early passage cells, a significantly higher proportion of late passage cells were positive for p16INK4A, and cells that stained positive for p16INK4A were DNA synthesis negative, corroborating the integrity of this SAPA pathway in HGSOC primary cells ( Fig. 1i-j) . We then explored the SA accumulation of permanent DNA damage foci termed DNA-SCARS (DNA segments with chromatin alterations reinforcing senescence) . To this end, we co-stained for 53BP1 and PML using immunofluorescence (IF), the colocalization of which has been shown to mark DNA-SCARS . Although DNA-SCARS were detected via colocaliztion, we quantified a non-significant increase in the proportion of cells that harbored three or more 53BP1 foci ( Fig. 1k-l), perhaps owing to high levels of basal DNA damage associated with HGSOC (Jin et al., 2016; Wang et al., 2017) . Lastly, we explored lamin B1 levels, shown to be downregulated in senescent cells (Freund et al., 2012) , and found that late passage HGSOC cells strongly downregulate nuclear lamin B1 as compared to their early passage counterparts ( Fig. 1m-n, Fig.   S2d ). Taken together, these data suggest that most if not all HGSOC primary cells retain the ability to undergo culture stress-induced senescence, and this senescence is associated with SAPA, SA-β-Gal, nuclear lamina alterations, the expression of p16INK4A, and perhaps the accumulation of further DNA-damage.
HGSOC primary cultures undergo TIS in response to DNA damage and chemotherapy
We next tested whether HGSOC primary cells undergo senescence in response to DNA damage induced by therapy, a phenomenon termed therapy-induced senescence (TIS). chemotherapy in patients (Heijns et al., 2008; Sakai et al., 2001; Siddiqui et al., 1997; van der Vijgh, 1991; Wiernik et al., 1987) . We then evaluated senescence hallmarks 8 days after the beginning of treatments. For both IR and CP, when compared to their controls, treated cells stained positive for SA-β-Gal (Fig. 2a-c) , were largely positive p16INK4A, negative for DNA synthesis (Fig. 2d-f ), exhibited increased DNA-SCARS ( Fig. 2g-h, Fig. S3a ), and expressed lower levels of nuclear lamin B1 (Fig. 2i-j, Fig. S3b ), validating the presence of senescence hallmarks. Senescence induced by DNA damage has been well described to be associated with a SASP (Malaquin et al., 2015; Nakamura et al., 2008) . Thus, we probed the secretome in three HGSOC primary cultures (TOV3011D, TOV2267, TOV2356) using multiplex immunoassay for a variety of SASP factors. Eight days after treatments, in all three primary cultures, a strong upregulation of SASP factors was detected, although specific factors differed slightly between treatments and individual cultures ( Fig. 3a-c) , consistent with previously observed context-dependent variations in SASP (Coppe et al., 2010; Coppe et al., 2008; Malaquin et al., 2016) Therefore, HGSOC primary cells seem to undergo TIS in response to DNA damaging therapies, including treatment with a standard chemotherapeutic regimen.
HGSOC TIS renders cells sensitive to ABT-263
SAAR is a pharmacologically targetable senescence hallmark that represents an opportunity for treatment improvement (Chang et al., 2016; Wang et al., 2018) . For example, senescent cells can be selectively re-directed to death using senolytic compounds like ABT-263 that inhibit the antiapoptotic proteins Bcl-2 and Bcl-xL (Chang et al., 2016; Pan et al., 2017; Yosef et al., 2016; Zhu et al., 2016) . Given the unpredictable microenvironmental impact of the SASP on tissue microenvironments and the possibility that HGSOC cell SAPA is not permanently stable, we sought to determine whether ABT-263 could be used to clear senescent HGSOC cells. We first (Fig. 4a, c) . Similarly, pre-senescent TOV1294G and TOV513 cells were insensitive to ABT-263 at lower doses ( Fig. 4d-e TOV1294G and TOV513 HGSOC cells were selectively preferentially eliminated by a 5 µM ABT-263 treatment ( Fig. 4f-g ). Thus, in addition to developing a TIS phenotype in response to therapy, HGSOC primary cells develop a sensitivity to ABT-263, suggesting a senolytic pharmacological strategy could enhance cancer cell elimination during current therapies.
HGSOC tissues display senescence hallmarks following exposure to chemotherapy in patients
Given that TIS occurs in HGSOC primary cultures in response to chemotherapy regimens used in the clinic, we explored whether TIS also occur in patients as a response to treatment. We constructed a tissue microarray (TMA) from HGSOC tissues collected from 170 patients treated at the Centre hospitalier de l'Université de Montréal (CHUM): 85 patients who had undergone surgery prior to chemotherapy, providing pre-chemotherapy samples, and 85 patients who had undergone surgery after primary chemotherapy, providing post-chemotherapy samples. Clinical follow-up data was associated with each patient sample (Fig. S4 ). The TMA was stained using IF to detect SA biomarkers, digitalized at high resolution, and quantitatively analyzed. Tissue cores were identified, segmented into epithelial (i.e. cancer cells) and stromal compartments using epithelial markers (cytokeratin CK7, 18, and 19), further segmented into nuclear and extranuclear compartments using DAPI (nuclear DNA signal), and categorized in specific compartments (i.e. total epithelial, epithelial nuclear, total stromal, and stromal nuclear; Fig. 5a ).
As expected for ovarian cancer (McCluggage et al., 2002) chemotherapy caused a significant reduction in the relative epithelial surface area within tumor tissues also reflected by the overall diminishment in total core mean fluorescent intensity (MFI) for cytokeratins or E-Cadherin (epithelial), and increased vimentin (stromal) (Fig. 5b ). We first explored senescence biomarkers' in tissue compartments using matched pre-and post-chemotherapy samples collected from the same patients, termed paired samples (limited availability). Interestingly, the MFI of epithelial nuclear laminB1 and Ki67 consistently decreased, while total epithelial IL6 consistently significantly in post-chemotherapy samples, whereas total epithelial IL6 increased ( Fig. 5f ).
There was no change in apoptosis levels as measured using caspase 3 activation (cleavage).
Interestingly, total epithelial vimentin was found to increase post-chemotherapy ( Fig. 5f ),
suggesting epithelial-to-mesenchymal transition (Huang et al., 2012; Lamouille et al., 2014) , a phenomenon also linked to paracrine effects of the SASP (Malaquin et al., 2013; Parrinello et al., 2005; Sun et al., 2012) . On the other hand, and unlike results observed in primary cultures, no significant differences were observed for epithelial nuclear p16INK4A or total epithelial IL8 between pre-and post-chemotherapy samples ( Fig. 5f ). Similarly, trends in the MFI of several SA biomarkers were consistent with senescence in the tumor stroma. In particular, stromal nuclear Ki67 and lamin B1 decreased, while total stromal IL8 increased (Fig. 5g ). Unlike epithelial tumoral tissue, we observed slightly increased apoptosis rates in the stroma, but no significant difference was found in stromal p16INK4A, IL6, or vimentin between pre-and postchemotherapy tissues (Fig. 5g ). Overall, these findings offer support to the idea that TIS occurs as a response to treatment in HGSOC cells in vitro, and in patient, suggesting TIS is an important response to current HGSOC chemotherapy treatment.
Senescence-associated biomarker levels in post-chemotherapy HGSOC tissues correlate with 5-year survival
Whether senescence is beneficial or detrimental during human cancer treatment remains unknown. To determine how TIS may influence patient's clinical course after treatment, we split patients from the post-chemotherapy group into high and low expressors of SA biomarkers and compared 5-year overall survival between the two groups using Kaplan-Meier analysis. Cutoff values for high-and low-expressors were determined via receiver operating characteristics (ROC) analyses. We find that low-expressors of epithelial nuclear lamin B1 post-chemotherapy, a sign of senescence, display improved 5-year overall survival as compared to high-expressors ( Fig. 6a) . Accordingly, high-expressors of epithelial nuclear p16INK4A, another sign of senescence, had improved survival in relation to low-expressors (Fig. 6b) . Moreover, patients with low epithelial nuclear Ki67 MFI reflecting reduced proliferation trended towards improved 5-year overall survival, but the difference between the groups was not significant (Fig. 6c) .
While senescence-associated markers in the epithelium were predictive of 5-year overall survival, no marker in the stroma other than vimentin could significantly predict survival ( Fig. 6d Calvo et al. / 2018
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and Fig. S6a ). Overall, a TIS response to chemotherapy appears associated with a positive prognosis for the patients.
DISCUSSION
In this study we demonstrate that HGSOC primary cells taken from highly aggressive and fatal human cancers respond to chemotherapy by triggering TIS including most senescence hallmarks.
Considering senescence is often driven by the p16/Rb and p53/p21 signaling cascades (Beausejour et al., 2003; Campisi and d'Adda di Fagagna, 2007; Narita et al., 2003; Rodier et al., 2007) , and that TP53 is rendered dysfunctional through a multitude of mechanisms in nearly all HGSOC (Ahmed et al., 2010; Cancer Genome Atlas Research, 2011; Jones and Drapkin, 2013) , it is perhaps not surprising that we found chemotherapy (CP) and IR promote p16INK4A-associated HGSOC senescence. Indeed, the key senescence tumor suppressor p16INK4A is rarely mutated in HGSOC (Fig. S2c) , and its diffuse expression is used by pathologists to help differentiate HGSOC from other ovarian cancer subtypes (Kurman et al., 2014) , raising the intriguing possibility that HGSOC cells maintain p16INK4A functions for cell cycle control in the absence of other TP53-associated DNA repair checkpoints, simultaneously preserving a capacity to undergo senescence in response to acute genome stress. A parallel non-exclusive possibility is that the p16/Rb pathway is inherently subverted downstream of p16INK4A in HGSOC, as often happen in HPV-induced cancers (Dyson et al., 1989; Sano et al., 1998; Ukpo et al., 2011) , explaining low mutation rates of CDKN2A. Supporting both possibilities, our attempts to immortalize HGSOC cells through simple shRNA knockdown of p16INK4A failed in 2/3 primary culture tested (data not shown), suggesting that SAPA pathways other than the traditional p16/Rb and p53/p21 cascades remain to be identified in this context. In summary, the evidence presented here of p16INK4A-associated replicative senescence (>90% of primary cultures) combined with the low CDKN2A mutation penetrance in HGSOC patients (3-5%)
suggests that the majority of HGSOC tumors retain the ability to undergo context-dependent TIS, providing treatment enhancement opportunities around pharmacological senescence manipulation.
In general, ethical and clinical considerations often preclude the collection of solid tumor tissue during chemotherapy regimens. HGSOC presents a particular clinical opportunity in that patients undergo either neoadjuvant chemotherapy followed by debulking surgery or primary debulking surgery followed by adjuvant chemotherapy (Kehoe et al., 2015; Vergote et al., 2010 (Coppe et al., 2010; Gilbert and Hemann, 2010; Rodier et al., 2009; Xue et al., 2007) , further guiding potential senescence pharmacological avenues toward SAPA reinforcement, SASP manipulation, and potential senescent cancer cell elimination via senolysis (Chang et al., 2016; Laberge et al., 2015; Moiseeva et al., 2013; Pan et al., 2017; Rader et al., 2013; Xu et al., 2015; Yosef et al., 2016; Zhu et al., 2016) .
Of course, several observations were made that raise unanswered questions. For instance, why is p16INK4A upregulation not observed in TIS patient tissues, while it is readily observed in all TIS primary HGSOC cultures? It is important to note that post-chemotherapy tissues were collected a minimum of four weeks after the most recent chemotherapy cycle, as per standard clinical protocols to allow patients recovered. During this treatment black box, maybe cells that upregulate p16INK4A relative to the baseline expression indeed become senescent, but may have been subjected to immune clearance (Kang et al., 2011; Xue et al., 2007) or may have been lost by dilution to cell populations that have not efficiently activated TIS. In this context, it is also important to note that the post-treatment samples available for study are necessarily taken from patients with incomplete responses to chemotherapy (~75% of patients), thus it remains possible that tissues that have undergone a strong senescence response and subsequent immune clearance were underrepresented in this study. Conversely, it is possible that underrepresented tissues underwent cell fates other than senescence as well, such as apoptosis. Taken together, it is clear that a closer study of this immediate post-treatment period is paramount to improve our understanding of HGSOC TIS but it will require innovative clinical strategies to obtain he required human tissues. treated tumor implies the possibility that these influence other cells within the tumor in ways which alter treatment outcomes. For example, the DNA damage-induced secretion of IL6 in the senescent microenvironment of post-chemotherapy murine thymus is sufficient to create a protective niche for a subset of lymphoma cells that can cause cancer recurrence (Gilbert and Hemann, 2010; Rodier et al., 2009) . Similarly, the presence of senescent cells in post-therapy murine breast cancers has been shown to trigger increased SASP levels which are associated with cancer recurrence (Jackson et al., 2012) . Finally, the secretion of the SASP factor WNT16B
(wingless-type MMTV integration site family member 16B) by senescent stromal cells in posttherapy murine prostates provides direct support for continued growth of prostatic epithelial cancer cells. Notably, increased stromal WNT16B levels have also been detected in post-therapy human prostate, ovarian, and breast cancers (Sun et al., 2012) . Thus, senescence and its relationship with long-term treatment outcomes must be assessed in a context-dependent manner.
Except for the emerging vision presented here for HGSOC, this concept has yet to be thoroughly studied in human cancers.
In the case of HGSOC, given the unpredictable influence of senescent cells on the clinical course, we further show that the incorporation of senolytic drugs into treatment regimens could prove to be beneficial via enhanced elimination of senescent cells. Several teams have reported the selective toxicity of compounds such as ABT-263 toward senescent cells (Chang et al., 2016; Pan et al., 2017; Zhu et al., 2016) , and our results support the senolytic properties of this compound in the context of HGSOC. Research in this area is plentiful, and there exists a multitude of compounds with similar senolytic properties (Childs et al., 2017) . Furthermore, elimimation of senescent cells by genetic manipulation proved to be effective in reducing agingassociated pathologies and tumor cells (Baker et al., 2011; Cheng and Rodier, 2015; Kohli et al., 2018; Laberge et al., 2013) . Similarly, the use of a small molecule CDKi could be considered to strengthen p16INK4A-induced activities or epigenetic regulators to favor increased expression of p16 INK4A and other senescence genes (Bourdeau and Ferbeyre, 2016) prior to senolytic clearance.
In summary, results this study warrant the idea that senescence is a therapeutic target for novel treatment modalities in HGSOC.
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MATERIALS AND METHODS

Ethics statement
The CHUM institutional ethics committee approved this study. Informed consent from all patients was obtained before sample collection. Tumor and ascites samples were collected from patients following informed consent from the CHUM Department of Gynecologic Oncology.
Patients and tissue specimens
Tumor samples were obtained from patients who underwent surgery for ovarian cancer in the CHUM Department of Gynecologic Oncology between 1993 and 2014. Disease stages were defined using the International Federation of Gynecology and Obstetrics (FIGO) staging system and tumor histopathology was classified using World Health Organization (WHO) criteria.
Patient survival was calculated from the date of diagnosis, which corresponded to 3 months prior to surgery for post-chemotherapy samples. Five-year overall patient survival was defined as the time from diagnosis to death or last follow-up, up to a maximum follow-up of five years. Patients known to be alive at the time of analysis or 5 years after diagnosis were censored at the time of their last follow-up.
Pre-and post-chemotherapy epithelial ovarian tumor tissue microarray (TMA)
A gynecologic pathologist reviewed all cases. The grade and type of ovarian carcinoma were identified and areas of interest were marked on hematoxylin and eosin-stained slides. Two cores of 0.8-mm diameter for each tissue sample were arrayed onto recipient paraffin blocks. The final TMA was composed of 340 cores from 170 epithelial ovarian tumors (2 replicate cores per patient). Clinicopathological details of the cohort are summarized in Fig. S4 .
Immunofluorescence staining of TMA
The TMA was sectioned into 4-µm thick slices and processed/stained using a BenchMark XT automated stainer (Ventana Medical System Inc., Tucson, AZ, USA). Antigen retrieval was carried out with Cell Conditioning 1 (Ventana Medical System Inc.; no. 950-124) for 60 minutes.
The prediluted primary antibody was automatically dispensed and incubated for 60 minutes at 37°C. Primary antibodies used were mouse anti-p16INK4A monoclonal antibody (JC18) (Santa #A31571 Life technologies Inc., ON, Canada (anti-mouse)) were added for 45 minutes, followed by washing and blocking overnight at 4°C with diluted Mouse-On-Mouse reagent (Vector #MKB-2213). This was followed by an incubation of 60 minutes with an epithelial mask of 3 mouse monoclonal antibodies (anti-K7 clone OV/TL 12-30 (Thermofisher #MS-1352-P), anti-K18 clone DC-10 (Santa Cruz #sc6259), and anti-K19 clone ab-1 (Thermofisher #MS-198-P).
The Alexa-fluor 750 secondary antibody (#A21037 Life technologies Inc., ON, Canada) was incubated for 45 minutes, followed by DAPI staining for 5 minutes. Staining with sudan black 0.1% for 15 minutes to quench tissue autofluorescence was followed by coverslip mounting using Fluoromount Aqueous Mounting Medium (#F4680, Sigma). The full TMA was scanneddigitalized using a 20X 0.75NA objective with a resolution of 0.325 µm (BX61VS, Olympus).
Multicolor images were segmented and quantified using Visiopharm Integrator System (VIS) version 4.6.1.630 (Visiopharm, Denmark).
VIS analysis
Immunofluorescence scoring was performed using the VIS software. Briefly, VIS was used to measure the MFI of all pixels in original digitalized multicolor TMA images for a chosen region of a tissue sample (total tissue core or core sub-compartments as described for Fig. 5a ). Then, the MFIs corresponding to replicate total cores or selected core sub-compartments from the same patient are averaged to calculate one final mean MFI for each data point used in the presented analysis (See sFig. 7 for quality control correlation data on duplicate cores)
Statistical analysis for TMA
Statistical significance of differences in MFI between pre-and post-chemotherapy groups was calculated using the Mann Whitney test. Survival curves were plotted using Kaplan-Meier analyses and the log-rank test was used to test for significance. All statistical analyses were done ranging from 2 to 3. Primary cell cultures were derived from patient samples following procedures reported in our previous publications (Lounis et al., 1994) . Unless otherwise indicated, cells were cultured in OSE media supplemented with 15% fetal bovine serum (FBS) and 1% streptomycin in a 5% O2 incubator. Proliferation was assessed using population doubling (PD) according to the following formula: last PD + (Log (final cell number) -Log (initial cell number plated) x 3.32).
SA-β-gal staining
Senescence-associated β-galactosidase (SA-β-gal) was assessed as previously described (Laberge et al., 2013) . Pictures were taken with a Nikon Eclipse TE300 microscope (Nikon Instruments Inc. Melville, NY, U.S.A).
Irradiation and chemotherapy
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Cells were seeded in appropriate vessels. 48 hours after seeding, cells were treated with either 10
Gy of X-irradiation (IR) using a Cesium 137 irradiator, or a combination of carboplatin (10 µM) and paclitaxel (30 nM). Carboplatin and paclitaxel were removed after 12 hours. Senescence hallmarks were tested 8-10 days later as indicated.
Immunofluorescence staining of primary cell cultures
Cells were cultured in 4-or 8-well chamber slides (Nunc, Penfield, NY, USA). After treatment and incubation, cells were fixed in 10% formalin (Sigma) for 10 minutes and washed 3 times in PBS for 5 minutes at room temperature (RT) followed by incubation for 30 minutes in blocking buffer (1% IgG-free BSA, 4% donkey serum [Jackson ImmunoResearch, West Grove, PA, USA] in PBS), then by incubation with primary antibodies diluted in blocking buffer overnight at 4 °C.
Cells were then washed and incubated with secondary antibodies and Hoechst for 1 hour at RT. 
Real-time quantitative polymerase chain reaction (qRT-PCR)
RNA was extracted from cells or tissues using TRIzol reagent. Reverse transcription was performed using Invitrogen Superscrit III (#11752). qRT-PCR using Sybr green (Invitrogen, The SYBR® GreenER™ qPCR SuperMix kits) was performed with the following protocol: 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds each at 95°C, 30 seconds at 72°C, and 1 minute at 60°C. The primers used are listed in the table below. 
Gene expression analysis
RNA from HGSOC cultures were extracted and purified as previously described (Gambaro et al., 2015; Zietarska et al., 2007) and microarray experiments were performed at the McGill University and Genome Quebec Innovation Centre (genomequebec.mcgill.ca) using HG- U133A GeneChip arrays (Affymetrix®, Santa Clara, CA). Gene expression levels were calculated for each probe set from the scanned image by Affymetrix® GeneChip (MAS5) as previously described (Cody et al., 2007) . As reproducibility of expression data is variable at low raw expression values (Arcand et al., 2004) , normalized data points below 15 were reassigned a threshold value of 15 based on the mean expression value of the lowest reliability scores. Probe sets having these threshold values in all samples were not used for further the analysis..
Normalized gene expression data from 42 HGSOC primary cultures (sTable 1) was used to stratify expression clusters using unsupervised k-means (Gene Cluster 3.0) based on 177 E2F-target genes (Genes encoding cell cycle related targets of E2F transcription factors, M5925, http://software.broadinstitute.org/gsea/msigdb/cards/HALLMARK_E2F_TARGETS). Clustering results were generated using Java Treeview to highlight E2F-response clusters I, II, III; with cluster I reflecting high proliferation (high E2F-activity) and cluster II and III reflecting lower EF2-activiy ( Fig. s1a-b) . Early passage primary cultures from cluster I (≤50% replicative lifespan completed; n=5) were then compared to late passage primary cultures from cluster II-III (≥75% replicative lifespan completed; n=7) and the differential gene expression detected between these 2 groups (early versus late passage) compared using GSEA to 22 senescent signatures obtained from Hernandez-Segura's work (Hernandez-Segura et al., 2017)( Fig. s1c-d ).
Antibodies and reagents
Antibody against 53BP1 ( 
SASP profiling
SASP was prepared as previously described (Rodier, 2013) with the following adjustments: Cells were seeded and treated with paclitaxel/carboplatin (or not) as described above, followed by incubation in OSE medium with 15% FBS for another 8 days (media was changed every 2 days).
Sixteen hours before performing antibody array, the vessels were washed 3 times with PBS, and the media was replaced with serum-free media to generate serum-free conditioned media. Fresh conditioned media were collected and stored on ice for immediate use on multiplex ELISA, and cell numbers were counted. Multiplex secretome detection was performed according to the protocol provided by Meso Scale Discovery V-PLEX Human Biomarker (40-Plex Kit K15209D-2). In brief, 50-µl samples, diluted 1:2 or 1:4, were added to the wells. Plates were sealed and incubated for 2 hours at RT. After incubation, plates were washed 3 times with 150 µl of wash buffer per well, and 25 µl of detection antibody solution were then added to each well. The plates were incubated for another 2 hours at RT, followed by 3 times washing with wash buffer. Before reading, 150 µl of 2X read buffer T were added to each well. Finally, the plates were read on the MSD instrument, with signals normalized to cell number.
Measurements of relative growth and viability
Cells were seeded in 96-wells plates and cultured within an IncuCyte® Zoom live cell imager that captured phase contrast images every 2 hours (Essen Bioscience). 24 hours after seeding cells received genotoxic treatments as indicated. Using captured images, the relative cell confluence (confluence mask) was determined by an integrated confluence algorithm (Essen Bioscience). To track treatment response, the data is reported as relative cell confluence (fold change) representing the confluence at the end of the indicated treatments over confluence just before treatment is initiated. calculated using the paired t test for all panels except panel b, where the Kolmogorov-Smirnov statistic was used. n.s. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001. was quantified in a 6 µm wide area along the perimeter of the nuclear area. Statistical significance was calculated using the paired t test. * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001. Multiplex-based SASP profiling was performed on conditioned media from TOV2267, TOV2356, and TOV3011D HGSOC primary cultures treated (or not) with either 10 Gy IR (a) or carboplatin (10µM) and paclitaxel (30nM) (CP) for 12 hours (b). The conditioned medium was prepared 8 days following treatment (serum-free OSE medium for 16 hours). The heat-map colors indicate the relative fold change in protein levels (red for increased levels, blue for decreased levels relative to the control signal for each culture). Statistical significance was calculated using the unpaired t test. * p < 0.05; ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
